• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Anal Chim Acta . SERS-based lateral flow immunoassay for rapid and sensitive sensing of nucleocapsid protein toward SARS-CoV-2 screening in clinical

tetano

Editor, Senior Moderator
Anal Chim Acta


. 2025 Jul 22:1360:344149.
doi: 10.1016/j.aca.2025.344149. Epub 2025 May 2. SERS-based lateral flow immunoassay for rapid and sensitive sensing of nucleocapsid protein toward SARS-CoV-2 screening in clinical samples

Weixia Zhi[SUP] 1 [/SUP], Lingwei Wang[SUP] 1 [/SUP], Li Dai[SUP] 1 [/SUP], Jing Xu[SUP] 1 [/SUP], Tingting He[SUP] 1 [/SUP], Xiangxin Zong[SUP] 1 [/SUP], Jun Xu[SUP] 1 [/SUP], Huaihong Cai[SUP] 2 [/SUP], Jiang Pi[SUP] 3 [/SUP], Pinghua Sun[SUP] 4 [/SUP], Shanze Chen[SUP] 5 [/SUP], Xueqin Huang[SUP] 6 [/SUP], Haibo Zhou[SUP] 7 [/SUP]



Affiliations
Abstract

Early and accurate identification of SARS-CoV-2 infection is crucial for epidemic prevention and control. Lateral flow immunoassay (LFIA) has become the mainstream method for screening SARS-CoV-2 infection due to its rapid, simple and amenable for point-of-care detection (POCT), but still suffered from the poor sensitivity and accuracy. In this study, Au nanoparticles (NPs) with controllable Ag shell (Au@Ag) were manufactured via a seed-mediated growth method. The Au@Ag-based LFIA exhibited superb colorimetric (CM) signal and intense surface-enhanced Raman scattering (SERS) signal for dual-mode sensing of nucleocapsid protein (N protein), a naturally protein expression in vivo during SARS-CoV-2 infection. The limit of detection (LOD) of the SERS-LFIA mode was 2.16 pg/mL, which was around 150-time more sensitive than conventional visual CM-LFIA mode (300 pg/mL). More importantly, the proposed LFIA is capable of quantitatively detecting N protein-spiked real samples with satisfactory recoveries from 83 % to 91.4 %. Clinical pharyngeal swab samples of the infected patients (n = 20) and healthy subjects (n = 20) were effectively discriminated in the developed SERS-LFIA, where the negative accuracy rate was 100 % and the positive accuracy rate was 85 %, among which samples from P1, P18, and P19 were false-negative results. The results obtained from the LFIA immunoassay were in good agreement with the standard PCR method in clinic, and superior to those of the commercially colloidal gold strip by using the same antibodies. In conclusion, the LFIA proposed here can perform specific, rapid, and ultrasensitive analysis of N protein toward early warning of SARS-CoV-2 infection.

Keywords: Lateral flow immunoassay; POCT; SARS-CoV-2 detection; Surface-enhanced Raman scattering.

 
Back
Top Bottom